Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 6, 2016, Pages 2612-2617

  Park, Sang Jun ^a   Choi, Yewon ^b   Na, Young Mi ^a   Hong, Hye Kyoung ^a   Park, Ji Yeon ^a   Park, Kyu Hyung ^a   Chung, Jae Yong ^b   Woo, Se Joon ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Aflibercept; Anti vascular endothelial growth factor agent; Eylea; Intraocular Pharmacokinetics

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CHOROID; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; MAXIMUM PLASMA CONCENTRATION; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; RETINA; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RABBITS AND HARES; RETINAL DISEASES;

ANIMALS; AQUEOUS HUMOR; CHOROID; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTRAVITREAL INJECTIONS; RABBITS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DISEASES; VITREOUS BODY;

EID: 84968615985     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-19204     Document Type: Article

References (14)

1. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99:11393-11398.
2. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92:667-668.
3. Park SJ, Oh J, Kim YK, et al. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye (Lond). 2015;29:561-568.
4. Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37:1171-1174.
5. Niwa Y, Kakinoki M, Sawada T, Wang X, Ohji M. Ranibizumab and aflibercept: intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and nonvitrectomized macaque eyes. Invest Ophthalmol Vis Sci. 2015;56:6501-6505.
6. Ahn J, Kim H, Woo SJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. 2013;29:612-618.
7. Ahn SJ, Ahn J, Park S, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2014;55:567-573.
8. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
9. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114:855-859.
10. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-1266.
11. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50: 4807-4813.
12. Sinapis CI, Routsias JG, Sinapis AI, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol. 2011;5:697-704.
13. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009;26:1236-1260.
14. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res. 2012;29:236-250.